D R Bolin - JoVE Visualize

Showing results (11-20 of 20) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 20 results.

European Journal of Immunology|December 1, 1995

Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragmentsD Vidović, F Falcioni, B Siklodi, et al.

Biochemistry|March 21, 1989

Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamicsD C Fry, V S Madison, D R Bolin, et al.

Agents and Actions|January 1, 1993

Interleukin-1 beta induces cytosolic PLA2 in parallel with prostaglandin E2 in rheumatoid synovial fibroblastsK I Hulkower, J W Coffey, W Levin, et al.

Human Immunology|August 26, 1998

Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cellsB Siklodi, A B Vogt, H Kropshofer, et al.

The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994

Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxisM O'Donnell, R J Garippa, N Rinaldi, et al.

The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994

Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studiesM O'Donnell, R J Garippa, N Rinaldi, et al.

The Journal of Experimental Medicine|June 1, 1996

HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitisK Ito, H J Bian, M Molina, et al.

Nature Biotechnology|June 29, 1999

Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility moleculesF Falcioni, K Ito, D Vidovic, et al.

British Journal of Pharmacology|August 26, 2010

Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptorsS A Tannu, L M Renzetti, N Tare, et al.

Journal of Medicinal Chemistry|June 8, 2000

Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structuresD R Bolin, A L Swain, R Sarabu, et al.

Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 20 results.

European Journal of Immunology|December 1, 1995

Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragmentsD Vidović, F Falcioni, B Siklodi, et al.

Biochemistry|March 21, 1989

Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamicsD C Fry, V S Madison, D R Bolin, et al.

Agents and Actions|January 1, 1993

Interleukin-1 beta induces cytosolic PLA2 in parallel with prostaglandin E2 in rheumatoid synovial fibroblastsK I Hulkower, J W Coffey, W Levin, et al.

Human Immunology|August 26, 1998

Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cellsB Siklodi, A B Vogt, H Kropshofer, et al.

The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994

Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxisM O'Donnell, R J Garippa, N Rinaldi, et al.

The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994

Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studiesM O'Donnell, R J Garippa, N Rinaldi, et al.

The Journal of Experimental Medicine|June 1, 1996

HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitisK Ito, H J Bian, M Molina, et al.

Nature Biotechnology|June 29, 1999

Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility moleculesF Falcioni, K Ito, D Vidovic, et al.

British Journal of Pharmacology|August 26, 2010

Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptorsS A Tannu, L M Renzetti, N Tare, et al.

Journal of Medicinal Chemistry|June 8, 2000

Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structuresD R Bolin, A L Swain, R Sarabu, et al.

Pageof 2